Header Logo

Connection

JORGE E CORTES to Imidazoles

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Imidazoles.
JORGE E CORTES
Connection Strength
2.964
Imidazoles
  1. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
    View in: PubMed
    Score: 0.398
  2. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2014 02 06; 370(6):577.
    View in: PubMed
    Score: 0.299
  3. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica. 2013 Nov; 98(11):e141-2.
    View in: PubMed
    Score: 0.294
  4. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct; 98(10):e131.
    View in: PubMed
    Score: 0.292
  5. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013 Aug; 162(4):548-52.
    View in: PubMed
    Score: 0.285
  6. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
    View in: PubMed
    Score: 0.276
  7. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005 Apr 20; 23(12):2805-12.
    View in: PubMed
    Score: 0.161
  8. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
    View in: PubMed
    Score: 0.104
  9. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880.
    View in: PubMed
    Score: 0.093
  10. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 09; 48:84-91.
    View in: PubMed
    Score: 0.089
  11. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
    View in: PubMed
    Score: 0.087
  12. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
    View in: PubMed
    Score: 0.085
  13. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
    View in: PubMed
    Score: 0.081
  14. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
    View in: PubMed
    Score: 0.078
  15. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1599-607.
    View in: PubMed
    Score: 0.071
  16. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702.
    View in: PubMed
    Score: 0.062
  17. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
    View in: PubMed
    Score: 0.039
  18. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S30-5.
    View in: PubMed
    Score: 0.036
  19. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573.
    View in: PubMed
    Score: 0.029
  20. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
    View in: PubMed
    Score: 0.027
  21. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
    View in: PubMed
    Score: 0.023
  22. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656.
    View in: PubMed
    Score: 0.022
  23. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.
    View in: PubMed
    Score: 0.019
  24. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.